Trial Profile
Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2014
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms INTREPID
- Sponsors United Therapeutics Corporation
- 08 Aug 2014 New trial record
- 23 Mar 2012